Edesa Biotech (EDSA) Cash from Financing Activities (2013 - 2025)

Edesa Biotech has reported Cash from Financing Activities for 11 years, with the latest figure at $3.4 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 61.98% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.3 million (up 676.76% YoY) and the FY2025 annual result came in at $17.0 million, up 2776.69% from the prior year.
• Cash from Financing Activities improved to $3.4 million in Q4 2025 per EDSA's latest filing, from $186483.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $14.8 million in Q1 2025 and troughed at -$31435.0 in Q3 2024.
• A 5-year average of $2.8 million and a median of $576848.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 144318.53% in 2023, then tumbled 107.62% in 2024.
• Over 5 years, Cash from Financing Activities stood at $1.2 million in 2021, then surged by 137.02% to $2.9 million in 2022, then slumped by 89.5% to $305742.0 in 2023, then soared by 577.55% to $2.1 million in 2024, then soared by 61.98% to $3.4 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.4 million, $186483.0, and $14.8 million for Q4 2025, Q3 2025, and Q1 2025 respectively.